07:25 AM EDT, 03/26/2026 (MT Newswires) -- Kamada ( KMDA ) said Thursday that its plasma collection center in San Antonio, Texas, received approval from the US Food and Drug Administration, allowing it to begin commercial sales of normal source plasma.

The company said it received approval after the FDA made an on-site inspection in February.

Kamada ( KMDA ) said the 11,100-square-foot facility supports up to 50 donor beds, with a planned capacity of up to about 50,000 liters of plasma annually.

The company said it now plans to seek approval from the European Medicines Agency for the San Antonio facility.

At maximum capacity, the company expects the facility to generate annual normal source plasma sales of $8 million to $10 million, it said.